Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. and Intent to

  Allergan, Inc. Announces Expiration of Tender Offer for All Outstanding
  Shares of MAP Pharmaceuticals, Inc. and Intent to Exercise Top-Up Option to
  Effect a Short-Form Merger

Business Wire

IRVINE, Calif. -- March 1, 2013

Allergan, Inc. (NYSE: AGN) (“Allergan”) today announced the expiration of the
tender offer (the “Offer”) initiated by its wholly-owned subsidiary, Groundhog
Acquisition, Inc. (“Purchaser”), on January 31, 2013 to purchase all of the
outstanding shares of common stock of MAP Pharmaceuticals, Inc. (NASDAQ: MAPP)
(“MAP”) for $25.00 per share, net to the seller in cash, without interest and
less any applicable withholding taxes, as set forth in the Tender Offer
Statement on Schedule TO filed by Purchaser and Allergan with the U.S.
Securities and Exchange Commission on January 31, 2013. The Offer and
withdrawal rights expired at 12:00 midnight, New York City time, on the night
of February 28, 2013.

According to the final report of the depository for the Offer, as of the
expiration of the Offer, a total of 30,500,220 shares of MAP common stock
(including approximately 2,717,161 shares subject to guarantees of delivery)
were validly tendered and not properly withdrawn prior to the expiration of
the Offer, which represent approximately 85.5% of all outstanding shares of
MAP common stock and approximately 75.1% of all outstanding shares of MAP
common stock on a fully diluted basis. The aggregate number of shares of MAP
common stock validly tendered and not properly withdrawn pursuant to the Offer
satisfies the condition to the Offer that at least a majority of the
outstanding shares of MAP common stock (on a fully diluted basis) be validly
tendered and not properly withdrawn prior to the expiration of the Offer.
Accordingly, Purchaser has accepted for payment and will promptly pay for all
such tendered shares in accordance with the terms of the Offer.

Pursuant to the Agreement and Plan of Merger, dated as of January 22, 2013, by
and among Allergan, Purchaser and MAP (the “Merger Agreement”), following
consummation of the Offer, Allergan and Purchaser intend to promptly effect a
“short-form” merger of Purchaser with and into MAP under Delaware law (the
“Merger”), with MAP continuing as the surviving corporation and a wholly-owned
subsidiary of Allergan. In order to obtain a sufficient number of shares of
MAP common stock to accomplish the Merger pursuant to the “short-form” merger
procedures under Delaware law, Purchaser intends to exercise the “top-up”
option granted to it by MAP under the Merger Agreement (the “Top-Up Option”).
The Top-Up Option entitles Purchaser to purchase from MAP newly issued shares
of MAP common stock in an amount equal to the lowest number of shares that,
when added to the number of shares owned by Allergan and Purchaser at the time
of the exercise of the Top-Up Option, will constitute one share more than 90%
of the number of shares of MAP common stock then outstanding (after giving
effect to the issuance of such shares).

At the effective time of the Merger, any shares of MAP common stock not
purchased in the Offer, other than shares held by Allergan, Purchaser, MAP or
any of its wholly-owned subsidiaries, and any shares held by any MAP
stockholders who validly exercise their appraisal rights in connection with
the Merger, will be converted into the right to receive the same cash price
per share paid in the Offer ($25.00 per share), without interest and less any
applicable withholding taxes. Following the Merger, Allergan intends to cause
MAP’s common stock to be delisted from the NASDAQ Global Select Market.

About Allergan, Inc.

Allergan is a multi-specialty health care company established more than 60
years ago with a commitment to uncover the best of science and develop and
deliver innovative and meaningful treatments to help people reach their life’s
potential. Today, we have approximately 10,800 highly dedicated and talented
employees, global marketing and sales capabilities with a presence in more
than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals,
biologics, medical devices and over-the-counter consumer products, and
state-of-the-art resources in R&D, manufacturing and safety surveillance that
help millions of patients see more clearly, move more freely and express
themselves more fully. From our beginnings as an eye care company to our focus
today on several medical specialties, including eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics, obesity
intervention and urologics, Allergan is proud to celebrate more than 60 years
of medical advances and proud to support the patients and physicians who rely
on our products and the employees and communities in which we live and work.
For more information regarding Allergan, go to: www.allergan.com.

Forward-Looking Statements

This press release contains “forward-looking statements,” relating to the
acquisition of MAP by Allergan. All statements other than historical facts
included in this press release, including, but not limited to, statements
regarding the timing and closing of the merger transaction, exercise of the
Top-Up Option and the delisting of the MAP common stock from the NASDAQ Global
Select Market, and any assumptions underlying the foregoing, are
forward-looking statements. These statements are based on current expectations
of future events. If underlying assumptions prove inaccurate or unknown, or
unknown risks or uncertainties materialize, actual events or results could
vary materially from Allergan’s expectations and projections. Risks and
uncertainties include, among other things, the ability to effect the
transactions on a timely basis or at all, as well as other cautionary
statements contained elsewhere herein and in the companies’ periodic reports
filed with the SEC including current reports on Form 8-K, quarterly reports on
Form 10-Q and annual reports on Form 10-K. Given these uncertainties, you
should not place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Allergan expressly disclaims
any intent or obligation to update these forward-looking statements except as
required by law. Additional information about Allergan is available at
www.allergan.com or you can contact the Allergan Investor Relations Department
by calling (714) 246-4636. Additional information about MAP is available at
www.mappharma.com.

Contact:

D.F. King & Co., Inc., (212) 269-5550 or (800) 347-4750
Allergan Investor Relations, (714) 246-4636
Media Inquiries (Bonnie Jacobs), (714) 246-5134
 
Press spacebar to pause and continue. Press esc to stop.